Events & Ideas
To be presented at the 84th CPDD Annual Scientific Meeting, June 11-15, 2022.
In a Phase 2 clinical trial REL-1017 showed rapid, robust, and sustained efficacy as adjunctive treatment for Major Depressive Disorder (MDD) without opioid-like side effects.
June 11-15, 2022 | MINNEAPOLIS, MN
Jack Henningfield, August Buchhalter, and Ryan Lanier will be attending CPDD.
Schnoll S, Beck R, Henningfield J, Ashworth J. The 2022 revision is a positive step forward in addressing the challenges that worsened the disparities in access to pain medicines that resulted from the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain – United States. READ OUR COMMENT
MAY 23–24, 2022 | WASHINGTON, DC
Following a presentation of the results from a 2021 survey of key stakeholders which elicited expert opinions on best practices and metrics to assess the safety of psychedelic drugs within the context of a REMS, as well as the most effective structure for such programs (e.g., individual vs. shared REMS programs), panelists in this session will discuss the most relevant aspects for designing appropriate REMS programs for this new class of medicines.
Coe M, Ashworth J, Schnoll S, Henningfield J. Under the Food and Drug Administration Amendments Act of 2007, the FDA can require the use of risk evaluation and mitigation strategies (REMS) over and above professional labeling, to ensure that a drug’s benefits outweigh its risks. As of August 2021, there were 314 listings on clinicaltrials.gov… Read More
Henningfield JE, Apseloff G, Gorodetzky C, Pappagallo M, Shram M, de Martin S, Fant RV, Vocci F, Sapienza F, Kosten T, Huston J, Buchhalter AR, Ashworth J, Lanier R, Folli F, Traversa S, Inturrisi CE, Manfredi PL. We aimed to assess the human abuse potential (HAP) of REL-1017 in a single-dose, randomized, double-blind, double dummy,… Read More
Fields S, Henningfield J, Correa-Fernandez V, Davis D, de Dios M, Garcia-Romeu A, Heads A, Hood C, Hudzik T, Martinez S, Moreland A, Skinstad A, Wilkerson, Jr J. Presented at the American College of Neuropsychopharmacology 60th Annual Meeting, December 5–8, 2021.
Coker A, Yazar-Klosinski B, Emerson A, Doblin R, Coe M, Henningfield JA If MDMA is approved for therapeutic use by the FDA, then it must be removed from Schedule I and placed in the most appropriate schedule based in part on analysis of 8 factors listed in the CSA. Although further analyses will be considered… Read More